Balint Bettina, Meinck Hans-Michael
Sobell Department of Motor Neuroscience and Movement Disorders UCL Institute of Neurology Queen Square, London UK.
Neuroimmunology Group, Nuffield Department of Clinical Neurosciences John Radcliffe Hospital Oxford UK.
Mov Disord Clin Pract. 2018 Jul 19;5(4):394-401. doi: 10.1002/mdc3.12629. eCollection 2018 Jul-Aug.
Stiff person spectrum disorders (SPSD) are a group of rare conditions clinically characterized by stiffness, spasms, and heightened stimulus sensitivity. They also share a spectrum of antibodies.
We reviewed the literature and our own experience with the aim of providing a practical approach to the treatment of SPSD.
Because of the rarity of SPSD, there is little evidence to guide treatment decisions. The treatment of SPSD is based on the triad of symptomatic treatment, immunotherapy, and tumor treatment where appropriate. Moreover, the management involves continuous and appropriate monitoring of the symptoms of the disease, its autoimmune associations, and potential treatment side effects.
Here we delineated a pragmatic treatment approach to SPSD, based on our experience and existing literature. We also highlighted how our understanding of neuronal antibodies and their implications reflects on management considerations.
僵人谱系障碍(SPSD)是一组罕见疾病,临床特征为僵硬、痉挛和刺激敏感性增强。它们还存在一系列抗体。
我们回顾了文献及自身经验,旨在提供一种治疗SPSD的实用方法。
由于SPSD罕见,几乎没有证据可指导治疗决策。SPSD的治疗基于对症治疗、免疫治疗及必要时的肿瘤治疗这三者。此外,管理还包括持续且适当地监测疾病症状、其自身免疫关联以及潜在的治疗副作用。
在此,我们根据自身经验和现有文献,阐述了一种针对SPSD的实用治疗方法。我们还强调了我们对神经元抗体及其影响的理解如何反映在管理考量中。